TB Vaccine Development
To address the inadequate global control of TB, and HIV-associated TB, Professor McShane and her team have developed several new vaccines, the first of which is called Modified Vaccinia Ankara virus expressing antigen 85A (MVA85A). MVA85A was developed as a BCG boost to improve BCG-induced protection against M.tb. Any new vaccine regimen needs to undergo extensive testing. Once found to be effective, a new regimen will be licensed and made available to the public.
Questions regarding the disease transmission cycle, the host protective immune response and the development of vaccines safe in HIV-infected individuals still need to be addressed, before we will have an effective vaccine.
Since 2013, McShane's lab has been pursuing three separate ways to improve the MVA85A vaccine. The first way is to combine the vaccine with another virus that expresses the same antigen, to induce a stronger immune response in the host. The second way is to continue to test the effect of delivering MVA85A by aerosol, as opposed to intradermal injection. Finally, the third way to improve MVA85A is to identify additional novel protective antigens, or molecules that are able to protect the host against infectious and non-infectious diseases, to add in to the Ag85A already in these vaccines.
Keywords: AEROSOL DELIVERY; BCG-INDUCTED PROTECTION; CLINICAL TRIALS; IMMUNE RESPONSE; IMMUNOLOGY; MYCOBACTERIUM TUBERCULOSIS; NOVEL PROTECTIVE ANTIGENS; TB; TUBERCULOSIS; VACCINATION; VACCINE; VACCINOLOGY; WELLCOME TRUST
Document Type: Research Article
Publication date: March 1, 2018
Impact is a series of high-quality, open access and free to access science reports designed to enable the dissemination of research impact to key stakeholders. Communicating the impact and relevance of research projects across a large number of subjects in a content format that is easily accessible by an academic and stakeholder audience. The publication features content from the world's leading research councils, policy groups, universities and research projects. Impact is published under a CC-BY Creative Commons licence.
- Subscribe to this Title
- Terms & Conditions
- Disseminating research in Impact
- Information about Impact
- Ingenta Connect is not responsible for the content or availability of external websites